Portrazza Side Effects
Generic name: necitumumab
Medically reviewed by Drugs.com. Last updated on Feb 12, 2023.
Note: This document contains side effect information about necitumumab. Some dosage forms listed on this page may not apply to the brand name Portrazza.
Applies to necitumumab: intravenous solution.
Intravenous route (Solution)
Cardiopulmonary arrest and/or sudden death have been reported with necitumumab in combination with gemcitabine and cisplatin. Monitor serum electrolytes, including serum magnesium, potassium, and calcium. Hypomagnesemia has been reported with necitumumab plus gemcitabine and cisplatin. Monitor for hypomagnesemia, hypocalcemia, and hypokalemia prior to each necitumumab dose and for at least 8 weeks after discontinuation. Withhold treatment if grade 3 or 4 electrolyte abnormalities occur.
Serious side effects of Portrazza
Along with its needed effects, necitumumab (the active ingredient contained in Portrazza) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking necitumumab:
- Abdominal or stomach cramps
- decreased urine
- difficulty with breathing
- dry mouth
- increased thirst
- irregular heartbeat
- loss of appetite
- mood or mental changes
- muscle cramps in the hands, arms, feet, legs, or face
- muscle pain or muscle spasms (tetany) or twitching
- nausea or vomiting
- numbness and tingling around the mouth, fingertips, or feet
- unusual tiredness or weakness
- back pain
- chest pain or discomfort
- chest tightness
- difficulty with speaking
- dizziness or lightheadedness
- double vision
- fast heartbeat
- heart stops
- inability to move the arms, legs, or facial muscles
- no breathing
- no pulse or blood pressure
- pain or discomfort in the arms, jaw, back, or neck
- pain, redness, or swelling in the arm or leg
- pains in the chest, groin, or legs, especially the calves of the legs
- severe headaches of sudden onset
- slow speech
- sudden loss of coordination
- sudden onset of slurred speech
- sudden shortness of breath or troubled breathing
- sudden vision changes
- trouble breathing
Other side effects of Portrazza
Some side effects of necitumumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
- Blemishes on the skin
- burning, dry, or itching eyes
- decreased weight
- discharge or excessive tearing
- dry skin
- itching skin or rash
- loosening of the fingernails
- rash with flat lesions or small raised lesions on the skin
- redness or soreness around the fingernails
- redness, pain, or swelling of the eye, eyelid, or inner lining of the eyelid
- swelling or inflammation of the mouth
For Healthcare Professionals
Applies to necitumumab: intravenous solution.
Common (1% to 10%): Venous thromboembolic events (VTE), arterial thromboembolic events (ATE), phlebitis
Frequency not reported: Cardiopulmonary arrest[Ref]
Very common (10% or more): Rash (44%), dermatitis acneiform (15%)
Common (1% to 10%): Acne, pruritus, dry skin, skin fissures[Ref]
Very common (10% or more): Vomiting (29%), diarrhea (16%), stomatitis (11%)
Frequency not reported: Infusion related reactions[Ref]
Very common (10% or more): Headache (11%)
Common (1% to 10%): Dysgeusia[Ref]
Common (1% to 10%): Conjunctivitis (includes conjunctivitis, eye irritation, vision blurred, conjunctivitis bacterial, dry eye, visual acuity reduced, blepharitis, allergic blepharitis, conjunctiva hemorrhage, eye infection, eye pain, lacrimation increased, ocular hyperemia, Sjogren's syndrome, visual impairment, and eye pruritus)
Frequency not reported: Eyelash trichomegaly[Ref]
Frequency not reported: Non-Squamous NSCLC -increased toxicity and increased mortality[Ref]
Very common (10% or more): Hemoptysis (10%)
Common (1% to 10%): Hypersensitivity reactions[Ref]
Common (1% to 10%): Muscle spasms[Ref]
Common (1% to 10%): Pyrexia[Ref]
More about Portrazza (necitumumab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: EGFR inhibitors
- En español
Related treatment guides
1. British Medical Association. Royal Pharmaceutical Society of Great Britain. Joint Formulary Committee. British National Formulary. http://bnf.org/bnf/ 2006.
2. Product Information. Portrazza (necitumumab). Eli Lilly and Company. 2015.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.